April 28, 2020 / 11:54 AM / a month ago

BRIEF-Kiniksa Reports Q1 2020 Financial Results

April 28 (Reuters) - Kiniksa Pharmaceuticals Ltd:

* KINIKSA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CORPORATE AND PIPELINE ACTIVITY

* KINIKSA PHARMACEUTICALS LTD - COVID-19 HAS NOT IMPACTED KINIKSA’S FINANCIAL GUIDANCE OR CHANGED COMPANY’S TIMELINES FOR CLINICAL DATA IN 2020, TO DATE.

* KINIKSA PHARMACEUTICALS LTD - QTRLY LOSS PER SHARE $0.48

* KINIKSA PHARMACEUTICALS LTD - PREPARING REGISTRATIONAL DEVELOPMENT PROGRAM OF MAVRILIMUMAB IN PATIENTS WITH COVID-19 PNEUMONIA AND HYPERINFLAMMATION

* KINIKSA PHARMACEUTICALS LTD - PHASE 2 TRIAL OF VIXARELIMAB IN PRURIGO NODULARIS MET PRIMARY EFFICACY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below